Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Link opens in a new tab
Search content at UTMB Health Research Expert Profiles
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Emerging infections in burns
Ludwik K. Branski
, Ahmed Al-Mousawi
, Haidy Rivero
, Marc G. Jeschke
, Arthur P. Sanford
, David N. Herndon
Surgery
Research output
:
Contribution to journal
›
Review article
›
peer-review
304
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Emerging infections in burns'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Emerging Infections
100%
Colistin
100%
Vancomycin
57%
Piperacillin-tazobactam
57%
Burn Patients
42%
Mortality Rate
42%
Morbidity Rate
28%
Highly Effective
28%
Effective Antibiotics
28%
Pseudomonas Infections
28%
Candida
28%
Multiresistant
28%
Multidrug-resistant Gram-negative Bacteria
28%
Acinetobacter Infections
28%
Hospital Stay
14%
Major Contributor
14%
Neurotoxicity
14%
Total Body Surface Area
14%
Treatment Strategy
14%
Antibiotics
14%
Systemic Infection
14%
Severe Burns
14%
High Risk
14%
Acute Hospital
14%
Severely Burned Patients
14%
Burn Wound Infection
14%
Pseudomonas Aeruginosa (P. aeruginosa)
14%
Methicillin-resistant Staphylococcus Aureus Infection
14%
Bacterial Infection
14%
High Efficiency
14%
Infection Control
14%
Treatment Group
14%
Antimicrobial Therapy
14%
Severe Infection
14%
Gram-positive
14%
No Significant Difference
14%
Voriconazole
14%
New Agents
14%
Definitive Diagnosis
14%
Full-thickness Burns
14%
Surgical Care
14%
Multidrug-resistant Organisms
14%
Gram-negative Organisms
14%
Isolation Method
14%
Local Infection
14%
Ventilatory Support
14%
Hospital Course
14%
Amphotericin B
14%
Fluid Management
14%
Aspergillus
14%
Fusarium
14%
Hepatic Toxicity
14%
Standard Antibiotics
14%
Aspergillus Spp
14%
Antibiotic Regimen
14%
Fungal Pathogens
14%
Multidrug-resistant Pathogens
14%
Nephrotoxicity
14%
Fungal Strains
14%
Clindamycin
14%
Multidrug-resistant Staphylococcus Aureus
14%
Rational Antibiotic Use
14%
Control Protocol
14%
Acinetobacter
14%
Oxazolidinone
14%
Reserve Antibiotics
14%
Streptogramins
14%
Prudent Use of Antibiotics
14%
Antifungal Compounds
14%
Multidrug-resistant S. Aureus
14%
Gram-positive Infections
14%
Burn Care Provider
14%
Pharmacology, Toxicology and Pharmaceutical Science
Burn
100%
Infection
100%
Colistimethate
87%
Vancomycin
50%
Piperacillin Plus Tazobactam
50%
Infectious Agent
37%
Antibiotics
37%
Mortality Rate
37%
Staphylococcus Aureus
25%
Gram Negative Bacterium
25%
Candida
25%
Pseudomonas Infection
25%
Aspergillus
25%
Acinetobacter Infection
25%
Neurotoxicity
12%
Bacterial Infection
12%
Pseudomonas aeruginosa
12%
Burn Infection
12%
Sepsis
12%
Methicillin Resistant Staphylococcus Aureus Infection
12%
Antimicrobial Therapy
12%
Mould
12%
Amphotericin B
12%
Antifungal Agent
12%
Nephrotoxicity
12%
Clindamycin
12%
Acinetobacter
12%
Streptogramin Derivative
12%
Oxazolidinone Derivative
12%
Gram Positive Infection
12%
Voriconazole
12%
Fusarium
12%
Treatment Group
12%
Hepatic Toxicity
12%
Medicine and Dentistry
Thermal Burn
100%
Infection
100%
Colistimethate
87%
Vancomycin
50%
Piperacillin/Tazobactam
50%
Mortality Rate
37%
Pathogen
37%
Antibiotics
37%
Gram-Negative Bacteria
25%
Staphylococcus Aureus
25%
Aspergillus
25%
Pseudomonas Infection
25%
Acinetobacter Infection
25%
Body Surface
12%
Sepsis
12%
Pseudomonas aeruginosa
12%
Burn Infection
12%
Bacterial Infection
12%
Methicillin Resistant Staphylococcus Aureus Infection
12%
Neurotoxicity
12%
Antimicrobial Therapy
12%
Voriconazole
12%
Antifungal Agent
12%
Amphotericin B
12%
Nephrotoxicity
12%
Clindamycin
12%
Acinetobacter
12%
Streptogramin
12%
Gram Positive Infection
12%
Oxazolidinone Derivative
12%
Infection Control
12%
Treatment Group
12%
Hepatic Toxicity
12%